Tajikistan State Register of Medicines 2026: Registration Entry and Public Disclosure Rules

1. Key takeaways

Tajikistan has established two systems: the State Register of Medicines and the public disclosure of registration information. Article 17(8) of Law No. 1893 provides that the list of registered medicines, pharmaceutical substances, medical goods and parapharmaceuticals is entered by the State Supervisory Body for Pharmaceutical Activity into the State Register of Medicines; Article 44(5) provides that information on state registration, decisions to revoke state registration, and non-conformity of medicines, medical goods and parapharmaceuticals with quality standards is published by the State Supervisory Body for Pharmaceutical Activity in the relevant publications. GRZAN notes: entry in the register is the statutory marker of completed registration, and also the core documentary basis for customs clearance, tendering and sales.

2. Legal basis

3. Expert insights

Insight 1: Article 1, item 41 defines the State Register of Medicines as a document containing information on medicines permitted for production and use, but the execution scope of Article 17(8) exceeds that definition. The definition clause speaks of medicines, whereas paragraph 8 requires the supervisory body to enter four categories — medicines, pharmaceutical substances, medical goods and parapharmaceuticals. This misalignment between definition and execution is a common phenomenon in Tajik regulatory texts. The practical handling of GRZAN is to follow the execution provision (Article 17(8)), meaning that medical goods should be entered in the register; after obtaining the registration certificate, enterprises should proactively verify whether the register information has been recorded.

Insight 2: There is a tension between confidential status under Article 17(7) and register entry under Article 17(8), and the boundary must be clarified at submission. Paragraph 7 permits information on registered products to be designated as confidential; paragraph 8 requires the list of registered products to be entered in the register. The way the two provisions connect is that the register records the fact of registration and basic identifying information, while core information such as formulations and compositions may be kept confidential upon application under paragraph 7. When applying for confidential status, enterprises should clearly state which fields are basic information open to the public and which are technical information for which confidentiality is sought.

Insight 3: Article 44(5) lists three categories of information as mandatory disclosure objects, among which revocation decisions and non-conformity with quality standards carry direct risk for enterprises. This means that once a product has its registration revoked or is found non-conforming with quality standards, the information will be published proactively by the supervisory body. Combined with the withdrawal mechanism of Article 21, the compliance risk in Tajikistan is a dual structure of administrative action plus information disclosure. GRZAN recommends that enterprises include this provision in their crisis management plans: what must be managed is not only the regulatory consequence but also the market and reputational impact after publication.

Insight 4: Article 26(4) and Article 29(1), item 5 together form a two-way information flow. Article 26(4) requires customs to notify the supervisory body of imports and exports; Article 29(1), item 5 grants citizens the right to inquire with the Ministry of Health and the supervisory body about safety, effectiveness and quality information. The former is an internal regulatory information flow; the latter is a public information flow. In theory, every import and export by an enterprise in Tajikistan is within the view of the supervisory body — this imposes a substantive requirement on batch-to-batch quality consistency.

4. Practical recommendations

1. Verify register entry immediately after obtaining the certificate. The standard action of GRZAN upon receiving a registration certificate is to confirm with the supervisory body that the registered products have been entered in the State Register of Medicines, and to retain a screenshot of the query or written confirmation as supporting evidence for subsequent customs clearance and tendering.
2. Divide public and confidential fields explicitly in the confidentiality application. When applying for confidential status under Article 17(7), submit a field list stating which information may be published and which is subject to confidentiality, avoiding conflict with the register entry obligation of Article 17(8).
3. Include Article 44(5) in crisis management plans. It is recommended that the quality system preset response processes for the two situations of registration revocation and non-conformity with quality standards, incorporating the communication lines to be used after information disclosure.
4. Establish a periodic review mechanism for register information. Review the enterprise information in the register quarterly to ensure product names, models and holder information match the actual situation, and process changes promptly under Article 17(12) whenever changes occur.

5. Verification checklist

• □ Confirmed the registered products have been entered by the supervisory body into the State Register of Medicines (Article 17(8))
• □ Obtained a query screenshot or written confirmation of the register entry
• □ Divided public and confidential fields explicitly in the confidentiality application (Article 17(7))
• □ Included the three categories of mandatory disclosure information of Article 44(5) in crisis management plans
• □ Established a quarterly review mechanism for register information
• □ Confirmed the mechanism of customs notifying the supervisory body of imports and exports (Article 26(4))
• □ Established an internal trigger process for registering changes (Article 17(12))

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com